| タイトル |
-
en
Correlation between elevation of serum antinuclear antibody titer and decreased therapeutic efficacy in the treatment of Behçet's disease with infliximab
|
| 作成者 |
|
| アクセス権 |
open access |
| 権利情報 |
-
en
The original publication is available at www.springerlink.com
|
| 主題 |
-
Other
ja
Behçet's disease
-
Other
en
Retinal vasculitis
-
Other
en
Uveitis
-
Other
en
Antinuclear antibody
-
Other
en
Infliximab
-
Other
en
Biomarker
-
Other
ja
Anti-TNF-α monoclonal antibody
-
NDC
496
|
| 内容注記 |
-
Abstract
en
Background: Infliximab, an anti-TNF-α monoclonal antibody, administered to Behçet's disease (BD) patients in Japan with refractory intraocular inflammation, has shown excellent clinical results. However, some patients demonstrate a decreased response to infliximab during the course of the treatment. In the present study, we investigated the correlation between this reduced therapeutic effect and elevation of the serum antinuclear antibody (ANA) titers in patients with BD who were undergoing infliximab therapy. Methods: Seventeen patients (14 males and 3 females) with uveitis in BD who were undergoing treatment with infliximab for 2 years or longer were enrolled. Their blood test results and clinical histories were obtained from medical records. Results: One patient (5.9%) was ANA-positive prior to the initiation of infliximab, and 11 patients (64.7%) developed positive ANA during the therapy. The appearance of ANA was observed 6 months after the initiation of the infliximab therapy, and its titres gradually increased. None of the patients showed lupus symptoms. Five patients (29.4%) have suffered from ocular inflammatory attacks since 6th month from the initiation of infliximab treatment and all of them were ANA-positive. In contrast, 4 patients (23.5%) who were ANA-negative experienced no ocular attacks during the follow-up period. Conclusions: Here we report the positive conversion and subsequent elevation of serum ANA titres in some patients with BD after the initiation of infliximab therapy. Since all recurrences of uveitis were shown only in the ANA-positive patients, serum ANA titre may be a helpful biomarker for predicting the recurrence of ocular attacks in BD patients treated with anti-TNF-α antibody therapies.
|
| 出版者 |
en
Springer Berlin / Heidelberg
|
| 日付 |
|
| 言語 |
|
| 資源タイプ |
journal article |
| 出版タイプ |
AM |
| 資源識別子 |
HDL
http://hdl.handle.net/2115/52973
|
| 関連 |
-
isVersionOf
DOI
https://doi.org/10.1007/s00417-011-1908-1
-
PMID
22234352
|
| 収録誌情報 |
-
-
en
Graefe's Archive for Clinical and Experimental Ophthalmology
-
巻250
号7
開始ページ1081
終了ページ1087
|
| ファイル |
|
| コンテンツ更新日時 |
2023-07-26 |
